ClinConnect ClinConnect Logo
Search / Trial NCT01415999

Cardiovascular Function in Adult Survivors of Childhood Malignancies

Launched by THE UNIVERSITY OF HONG KONG · Aug 11, 2011

Trial Information

Current as of August 02, 2025

Completed

Keywords

Anthracycline Cardiac Function Echocardiography Biomarkers

ClinConnect Summary

Incorporation of anthracyclines into chemotherapy protocols has improved the survival of children with solid tumours and haematological malignancies. Nonetheless, longitudinal studies have implicated the absence of a safe anthracycline dose that is free of cardiotoxicity. Substantial risk for cardiovascular disease has been shown recently in large cohorts of adult survivors of childhood and adolescent survivors. Serial monitoring of cardiac function is hence of paramount importance in childhood cancer survivors for early detection of myocardial damage and timely institution of interventions...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patients aged 18 to 35 years old
  • history of acute leukaemia diagnosed before 18 years old
  • completion of cancer directed therapy for at least 5 years.
  • Exclusion Criteria:
  • history of congenital heart disease
  • presence of syndromal disorder such as Down syndrome, neurofibromatosis, etc,
  • hypothyroidism not on replacement therapy
  • claustrophobia or other reasons rendering MRI assessment not feasible.

About The University Of Hong Kong

The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.

Locations

Hong Kong, Hong Kong, China

Patients applied

0 patients applied

Trial Officials

Yiu-fai Cheung, MD

Principal Investigator

The University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials